Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 150c; affirms guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $240.07 -2.73%
EPS Growth %: -20.5%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -20.5%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.68, $1.50 worse than the analyst estimate of $4.18. Revenue for the quarter came in at $901.98 million versus the consensus estimate of $953.95 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $18.15-$19.35, versus the consensus of $18.95. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.2 billion, versus the consensus of $4.095 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Chime to acquire Stride Bank for $590M in cash
- BMO Capital Starts Abercrombie & Fitch (anf) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
